FY2030 EPS Forecast for Moderna Cut by Analyst

Moderna, Inc. (NASDAQ:MRNA) – Research analysts at Brookline Capital Markets lowered their FY2030 earnings estimates for Moderna in a report released on Thursday, October 22nd. Brookline Capital Markets analyst L. Cann now forecasts that the company will earn $18.19 per share for the year, down from their prior estimate of $19.11. Brookline Capital Markets has a “Buy” rating on the stock. The consensus estimate for Moderna’s current full-year earnings is ($6.11) per share.

Moderna (NASDAQ:MRNA) last released its quarterly earnings results on Friday, July 31st. The company reported ($1.97) EPS for the quarter, beating the consensus estimate of ($2.03) by $0.06. The firm had revenue of $145.00 million for the quarter, compared to analyst estimates of $102.93 million. During the same quarter in the prior year, the business posted ($2.13) EPS. The firm’s quarterly revenue was up 2.1% compared to the same quarter last year.

A number of other equities research analysts have also recently commented on MRNA. Sanford C. Bernstein restated a “market perform” rating on shares of Moderna in a research report on Friday, September 25th. Bradesco Corretora upgraded Moderna to an “outperform” rating in a research note on Friday, August 28th. TD Cowen reaffirmed a “buy” rating on shares of Moderna in a report on Wednesday, October 21st. Singular Research raised Moderna to a “hold” rating in a report on Wednesday, September 23rd. Finally, William Blair cut Moderna from an “outperform” rating to a “market perform” rating in a research report on Tuesday. Six investment analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and four have assigned a Sell rating to the company. Based on data from MarketBeat.com, Moderna currently has an average rating of “Hold” and an average price target of $107.10.

Moderna Trading Up 4.6%

Shares of Moderna stock opened at $207.97 on Monday. The firm has a 50-day simple moving average of $176.73 and a two-hundred day simple moving average of $83.73. Moderna has a fifty-two week low of $22.28 and a fifty-two week high of $254.48.

Institutional Investors Weigh In On Moderna

A number of large investors have recently modified their holdings of MRNA. BlackRock Inc. purchased a new stake in Moderna during the 2nd quarter valued at about $2,142,877,000. Theleme Partners LLP purchased a new position in Moderna in the 2nd quarter worth approximately $564,272,000. Wellington Management Group LLP boosted its holdings in shares of Moderna by 4.4% during the 2nd quarter. Wellington Management Group LLP now owns 2,461,574 shares of the company’s stock worth $172,384,000 after purchasing an additional 103,977 shares during the last quarter. Merck & Co. Inc. acquired a new position in shares of Moderna during the 2nd quarter worth approximately $161,642,545. Finally, Bamco Inc. NY purchased a new stake in shares of Moderna in the second quarter valued at approximately $139,317,000. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Insider Buying and Selling

In other Moderna news, President Stephen Hoge sold 39,145 shares of the firm’s stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $220.72, for a total value of $8,640,084.40. Following the transaction, the president owned 1,636,565 shares in the company, valued at approximately $361,222,626.80. This trade represents a 2.34% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO James M. Mock sold 34,836 shares of the firm’s stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $134.49, for a total value of $4,685,093.64. Following the completion of the transaction, the chief financial officer owned 59,375 shares in the company, valued at $7,985,343.75. The trade was a 36.98% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 197,251 shares of company stock worth $33,875,904. Insiders own 10.80% of the company’s stock.

Trending Headlines about Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna and Merck’s Phase 3 INTerpath-001 trial showed that intismeran, combined with Keytruda, reduced the risk of melanoma recurrence or death by 42% versus Keytruda alone. The regimen also reduced the risk of distant metastasis or death by 38%, and the results were accepted for publication in The New England Journal of Medicine. Moderna Phase 3 Melanoma Vaccine Validation
• Positive Sentiment: CEO Stéphane Bancel said Moderna’s mRNA platform could support cancer vaccines beyond melanoma, including additional tumor types. Management continues to present the technology as a scalable platform with significant long-term commercial potential. Moderna CEO on Cancer Vaccine Potential
• Neutral Sentiment: One price target for Moderna’s depositary receipt was raised 14.39% to ARS11,759.61, indicating that some analysts remain constructive despite the recent volatility. Moderna Depositary Receipt Price Target
• Negative Sentiment: William Blair downgraded MRNA from Outperform to Market Perform, citing valuation after a roughly 545% year-to-date rally. The downgrade added to profit-taking pressure and reinforced concerns that much of the cancer-vaccine success is already reflected in the stock. William Blair Downgrades Moderna
• Negative Sentiment: The 42% recurrence reduction was below investor hopes for a result closer to the approximately 49% benefit seen in Phase 2. Overall-survival data are not yet mature, while Moderna remains unprofitable and must commercialize an individualized, patient-specific manufacturing process. Merck and Moderna Cancer Vaccine Results

Moderna Company Profile

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can stimulate immune responses or support the treatment of disease. The company’s research programs span infectious diseases, immuno-oncology, rare diseases, autoimmune conditions and other therapeutic areas.

Moderna’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults.